Technical Analysis for BGNE - BeiGene, Ltd.

Grade Last Price % Change Price Change
grade A 193.48 0.14% 0.28
BGNE closed up 0.14 percent on Tuesday, May 22, 2018, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical BGNE trend table...

Date Alert Name Type % Chg
May 22 Calm After Storm Range Contraction 0.00%
May 22 NR7 Range Contraction 0.00%
May 22 Inside Day Range Contraction 0.00%
May 22 Overbought Stochastic Strength 0.00%
May 21 Calm After Storm Range Contraction 0.14%
May 21 New 52 Week High Strength 0.14%
May 21 Stochastic Reached Overbought Strength 0.14%
May 21 Upper Bollinger Band Walk Strength 0.14%
May 21 Multiple of Ten Bearish Other 0.14%
May 21 Multiple of Ten Bullish Other 0.14%

Older signals for BGNE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Is BGNE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 202.88
52 Week Low 36.51
Average Volume 378,988
200-Day Moving Average 117.3937
50-Day Moving Average 171.6738
20-Day Moving Average 180.2745
10-Day Moving Average 185.047
Average True Range 8.3616
ADX 28.72
+DI 29.48
-DI 10.1
Chandelier Exit (Long, 3 ATRs ) 177.7952
Chandelier Exit (Short, 3 ATRs ) 185.6048
Upper Bollinger Band 197.2308
Lower Bollinger Band 163.3182
Percent B (%b) 0.89
BandWidth 18.811646
MACD Line 6.3708
MACD Signal Line 5.1886
MACD Histogram 1.1822
Fundamentals Value
Market Cap 7.71 Billion
Num Shares 39.8 Million
EPS -4.97
Price-to-Earnings (P/E) Ratio -38.93
Price-to-Sales 0.00
Price-to-Book 12.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 201.46
Resistance 3 (R3) 201.41 198.71 200.13
Resistance 2 (R2) 198.71 196.67 198.73 199.69
Resistance 1 (R1) 196.09 195.42 197.40 196.14 199.24
Pivot Point 193.39 193.39 194.04 193.41 193.39
Support 1 (S1) 190.77 191.35 192.08 190.82 187.72
Support 2 (S2) 188.07 190.10 188.09 187.27
Support 3 (S3) 185.45 188.07 186.83
Support 4 (S4) 185.50